{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T04:27:20Z","timestamp":1793766440170,"version":"4.6.1"},"reference-count":34,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011912","name":"Washington University in St Louis School of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011912","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.clgc.2026.102645","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T15:43:39Z","timestamp":1786722219000},"page":"102645","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-World Effectiveness and Tolerability of Belzutifan in Sporadic Clear Cell Renal Cell Carcinoma: A Retrospective Cohort Study With Exploratory Genomic Correlation"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2725-3812","authenticated-orcid":false,"given":"Parker","family":"Mathews","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Neiditz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0378-069X","authenticated-orcid":false,"given":"Phoenix","family":"Hollenbeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9387-0855","authenticated-orcid":false,"given":"Jeevan","family":"Rajkumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6388-5553","authenticated-orcid":false,"given":"Martin W.","family":"Schoen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8966-7631","authenticated-orcid":false,"given":"Russell K.","family":"Pachynski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1556-3100","authenticated-orcid":false,"given":"Eric","family":"Knoche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.clgc.2026.102645_bib0001","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"10.1016\/j.clgc.2026.102645_bib0002","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.molcel.2008.04.009","article-title":"Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway","volume":"30","author":"Kaelin","year":"2008","journal-title":"Mol Cell"},{"issue":"7456","key":"10.1016\/j.clgc.2026.102645_bib0003","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/nature12222","article-title":"Comprehensive molecular characterization of clear cell renal cell carcinoma","volume":"499","year":"2013","journal-title":"Nature"},{"issue":"7627","key":"10.1016\/j.clgc.2026.102645_bib0004","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/nature19795","article-title":"On-target efficacy of a HIF-2\u03b1 antagonist in preclinical kidney cancer models","volume":"539","author":"Cho","year":"2016","journal-title":"Nature"},{"issue":"7627","key":"10.1016\/j.clgc.2026.102645_bib0005","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nature19796","article-title":"Targeting renal cell carcinoma with a HIF-2 antagonist","volume":"539","author":"Chen","year":"2016","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.clgc.2026.102645_bib0006","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S1470-2045(12)70584-3","article-title":"Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation","volume":"14","author":"Kapur","year":"2013","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.clgc.2026.102645_bib0007","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1016\/S1470-2045(18)30648-X","article-title":"Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study","volume":"19","author":"Voss","year":"2018","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.clgc.2026.102645_bib0008","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.cell.2018.03.043","article-title":"Deterministic evolutionary trajectories influence primary tumor growth: tRACERx Renal","volume":"173","author":"Turajlic","year":"2018","journal-title":"Cell"},{"issue":"6377","key":"10.1016\/j.clgc.2026.102645_bib0009","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1126\/science.aan5951","article-title":"Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma","volume":"359","author":"Miao","year":"2018","journal-title":"Science"},{"issue":"14","key":"10.1016\/j.clgc.2026.102645_bib0010","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.clgc.2026.102645_bib0011","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.clgc.2026.102645_bib0012","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.clgc.2026.102645_bib0013","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.clgc.2026.102645_bib0014","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Motzer","year":"2019","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.clgc.2026.102645_bib0015","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.clgc.2026.102645_bib0016","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1056\/NEJMoa1510016","article-title":"Cabozantinib versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Choueiri","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.clgc.2026.102645_bib0017","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S1470-2045(19)30735-1","article-title":"Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study","volume":"21","author":"Rini","year":"2020","journal-title":"Lancet Oncol"},{"issue":"34","key":"10.1016\/j.clgc.2026.102645_bib0018","doi-asserted-by":"crossref","first-page":"5794","DOI":"10.1200\/JCO.2008.21.4809","article-title":"Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study","volume":"27","author":"Heng","year":"2009","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.clgc.2026.102645_bib0019","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1038\/bjc.2014.25","article-title":"The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: benchmarks for trial design","volume":"110","author":"Ko","year":"2014","journal-title":"Br J Cancer"},{"issue":"9","key":"10.1016\/j.clgc.2026.102645_bib0020","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1200\/JCO.2017.74.2627","article-title":"Phase I dose-escalation trial of PT2385, a first-in-class hypoxia-inducible factor-2\u03b1 antagonist in patients with previously treated advanced clear cell renal cell carcinoma","volume":"36","author":"Courtney","year":"2018","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.clgc.2026.102645_bib0021","doi-asserted-by":"crossref","first-page":"6876","DOI":"10.1021\/acs.jmedchem.9b00719","article-title":"3-[(1S,2S,3R)-2,3-Difluoro-1-hydroxy-7-methylsulfonylindan-4-yl]oxy-5-fluorobenzonitrile (PT2977), a hypoxia-inducible factor 2\u03b1 (HIF-2\u03b1) inhibitor for the treatment of clear cell renal cell carcinoma","volume":"62","author":"Xu","year":"2019","journal-title":"J Med Chem"},{"issue":"2","key":"10.1016\/j.clgc.2026.102645_bib0022","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1210\/endrev\/bnac025","article-title":"Hypoxia-inducible factor 2 alpha (HIF2\u03b1) inhibitors: targeting genetically driven tumor hypoxia","volume":"44","author":"Toledo","year":"2023","journal-title":"Endocr Rev"},{"issue":"5","key":"10.1016\/j.clgc.2026.102645_bib0023","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/s41591-021-01324-7","article-title":"Inhibition of hypoxia-inducible factor-2\u03b1 in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis","volume":"27","author":"Choueiri","year":"2021","journal-title":"Nat Med"},{"issue":"22","key":"10.1016\/j.clgc.2026.102645_bib0024","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1056\/NEJMoa2103425","article-title":"Belzutifan for renal cell carcinoma in von Hippel-Lindau disease","volume":"385","author":"Jonasch","year":"2021","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.clgc.2026.102645_bib0025","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1056\/NEJMoa2313906","article-title":"Belzutifan versus everolimus for advanced renal-cell carcinoma","volume":"391","author":"Choueiri","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.clgc.2026.102645_bib0026","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S1470-2045(24)00649-1","article-title":"Belzutifan plus cabozantinib as first-line treatment for patients with advanced clear-cell renal cell carcinoma (LITESPARK-003): an open-label, single-arm, phase 2 study","volume":"26","author":"Choueiri","year":"2025","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2026.102645_bib0027","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.euf.2024.09.007","article-title":"Belzutifan efficacy and tolerability in patients with sporadic metastatic clear cell renal cell carcinoma","volume":"11","author":"Wang","year":"2024","journal-title":"Eur Urol Focus"},{"issue":"2","key":"10.1016\/j.clgc.2026.102645_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2025.102498","article-title":"Clinical outcomes of targeted therapies following HIF-2\u03b1 inhibition in metastatic renal cell carcinoma: a real-world analysis","volume":"24","author":"Rioja","year":"2026","journal-title":"Clin Genitourin Cancer"},{"issue":"5","key":"10.1016\/j.clgc.2026.102645_bib0029","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1007\/s11096-025-01953-9","article-title":"A real-world pharmacovigilance study of belzutifan in renal cell carcinoma and von Hippel-Lindau disease: insights from the FDA Adverse Event Reporting System database","volume":"47","author":"Ye","year":"2025","journal-title":"Int J Clin Pharm"},{"issue":"6","key":"10.1016\/j.clgc.2026.102645_bib0030","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1093\/jjco\/hyag037","article-title":"Real-world outcomes of third-line systemic therapy after immune checkpoint inhibitor combinations and subsequent VEGFR-TKIs in advanced renal cell carcinoma","volume":"56","author":"Ishihara","year":"2026","journal-title":"Jpn J Clin Oncol"},{"issue":"2","key":"10.1016\/j.clgc.2026.102645_bib0031","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.eprac.2025.09.204","article-title":"Belzutifan for HIF2A-related pheochromocytoma and paraganglioma: a retrospective study of real-world data","volume":"31","author":"Alkaissi","year":"2025","journal-title":"Endocr Pract"},{"issue":"2","key":"10.1016\/j.clgc.2026.102645_bib0032","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.clgc.2026.102645_bib0033","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/14656566.2026.2627934","article-title":"Belzutifan monotherapy and combination therapies in renal cell carcinoma: a clinical trial perspective from the ARON working group","volume":"27","author":"Calabr\u00f2","year":"2026","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.clgc.2026.102645_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2025.155964","article-title":"Insights into the impact of chromosome 3p mutations in advanced renal cell carcinoma treated with immune-based combinations or targeted therapy: a single-center experience","volume":"270","author":"Rosellini","year":"2025","journal-title":"Pathol Res Pract"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155876732600145X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155876732600145X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T04:15:31Z","timestamp":1793765731000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S155876732600145X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":34,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S155876732600145X"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102645","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-World Effectiveness and Tolerability of Belzutifan in Sporadic Clear Cell Renal Cell Carcinoma: A Retrospective Cohort Study With Exploratory Genomic Correlation","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102645","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102645"}}